Announced details
Inventory management and in-hospital transport of specialty pharmaceuticals at medical institutions, and pharmaceutical quality control and traceability
Analyzed as having contributed to reducing disposal losses by approximately ¥7 billion annually (effect attributable to Cubixx)
Approximately 750 Cubixx units are in operation nationwide. The system has been adopted by approximately 60% of designated cancer hospitals and approximately 90% of National University Corporations.
Co-developed the VIXELL temperature-controlled pharmaceutical transport box with Panasonic Corporation.
Head office: Shinagawa-ku, Tokyo; Representative Director, President, Executive Officer and CEO: Toyoshima Akira (豊嶋明). Other company information: not disclosed.
The impact on business performance is Not disclosed
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Cubixx Link (キュービックス リンク), Cubixx system, VIXELL |
| Counterparty | Panasonic Corporation |
| Counterparty overview | Head office: Shinagawa-ku, Tokyo; Representative Director, President, Executive Officer and CEO: Toyoshima Akira (豊嶋明). Other company information: not disclosed. |
| Relationship with the Company | Co-developed the VIXELL temperature-controlled pharmaceutical transport box with Panasonic Corporation. |
| Launch date | 1 October 2026 (scheduled) |
| Applicable area | Inventory management and in-hospital transport of specialty pharmaceuticals at medical institutions, and pharmaceutical quality control and traceability |
| Quantitative Effects | Analyzed as having contributed to reducing disposal losses by approximately ¥7 billion annually (effect attributable to Cubixx) |
| Usage history | Approximately 750 Cubixx units are in operation nationwide. The system has been adopted by approximately 60% of designated cancer hospitals and approximately 90% of National University Corporations. |
| Impact on Business Performance | The impact on business performance is Not disclosed |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To ensure traceability during in-hospital transport after pharmaceuticals have been removed from Cubixx, and to address the risk of disposal losses arising from postponed administration or prescription changes due to patients’ conditions.